INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Digital Therapeutics as Adjuncts to Pharmacotherapy: Regulatory Landscape, Clinical Evidence, and Commercial Challenges

Chaya Rani*, Amit Kumar[2], Akshay Sharma[3], Gurvinder Pal Singh[4]

**Pharmacy Academy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, INDIA.*
[2]Institute of Pharmaceutical Sciences, Shri Ramswaroop Memori University, Barabanki, India
[3]Department of Pharmaceutics, Shree ji institute of pharmaceutical education and research Bilari Mmoradabad, Uttar Pradesh, India
[4]Sharda School of Pharmacy, Sharda University, Agra, Uttar Pradesh, India

ARTICLE INFO

Published: 30 May. 2026
Keywords:
Digital therapeutics; Pharmacotherapy; Regulatory framework; Medication adherence; Software as a medical device.
DOI:
10.5281/zenodo.20459401

ABSTRACT

Digital therapeutics (DTx) have emerged as a novel class of evidence-based, software-driven interventions designed to prevent, manage, or treat medical disorders. Unlike general digital health applications, DTx are increasingly positioned as adjuncts to pharmacotherapy, enhancing therapeutic outcomes through improved medication adherence, real-time monitoring, and personalized behavioral interventions. This review aims to critically examine the evolving role of DTx in combination with conventional drug therapy, with a focus on their clinical effectiveness, regulatory status, and commercial viability. Current clinical evidence from randomized controlled trials and real-world studies suggests that DTx can significantly improve disease management in areas such as diabetes, mental health disorders, and cardiovascular conditions. However, challenges remain regarding the standardization of clinical validation, long-term efficacy, and integration into routine healthcare practice. The regulatory landscape for DTx is rapidly developing, with frameworks such as Software as a Medical Device (SaMD) guiding approvals, though inconsistencies across regions persist. From a commercial perspective, issues related to reimbursement, pricing models, and market adoption continue to influence scalability. Additionally, concerns surrounding data privacy, cybersecurity, and patient accessibility must be addressed to ensure equitable implementation. Overall, DTx represent a promising adjunct to pharmacotherapy, but their widespread adoption will depend on robust clinical evidence, harmonized regulatory pathways, and sustainable business models.

***Corresponding Author:** Chaya Rani
Address: *Pharmacy Academy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, INDIA*
Email ✉: rinichaya125@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

Definition and Scope of Digital Therapeutics (DTx)

Digital therapeutics (DTx) are a class of evidence-based therapeutic interventions delivered through high-quality software programs to prevent, manage, or treat medical disorders or diseases. Unlike general wellness or fitness applications, DTx are grounded in scientific validation and are typically supported by clinical evidence demonstrating their safety and efficacy. These interventions often utilize technologies such as mobile applications, web-based platforms, and connected devices to deliver structured therapeutic content, including behavioral modification strategies, cognitive interventions, and real-time feedback mechanisms[1].

The scope of DTx spans a wide range of therapeutic areas, including chronic diseases (e.g., diabetes and cardiovascular disorders), mental health conditions (e.g., depression and anxiety), neurological disorders, and substance use disorders. They may be used as standalone treatments or, more commonly, as adjuncts **to** pharmacotherapy, enhancing the effectiveness of conventional drug therapy by improving medication adherence, enabling continuous patient monitoring, and supporting personalized treatment approaches[2].

From a regulatory standpoint, many DTx products are classified as Software as a Medical Device (SaMD), requiring rigorous clinical evaluation and approval by regulatory authorities prior to market entry. Their scope also includes integration with healthcare systems, enabling data sharing with clinicians and facilitating informed clinical decision-making. Digital therapeutics represent a significant advancement in modern healthcare, bridging traditional pharmacological treatment with digital innovation and contributing to improved patient outcomes and healthcare delivery[3].



Figure 1: Digital health Ecosystem



Figure 2: Conceptual position of Digital Therapeutics (DTx) in relation to the existing therapeutic options.

Distinction from Digital Health and Wellness Apps

Digital therapeutics (DTx) are distinctly different from general digital health tools and wellness applications in terms of purpose, evidence base, regulatory oversight, and clinical integration. While all DTx fall under the broader umbrella of digital health, not all digital health applications qualify as therapeutics[4].

Digital health is a broad category that includes mobile health (mHealth), telemedicine, wearable devices, and health information systems aimed at improving healthcare delivery and monitoring. Within this spectrum, wellness apps are typically designed to support general health and lifestyle goals such as fitness tracking, diet management, sleep improvement, or stress reduction. These applications are usually non-clinical, do not claim to treat or manage diseases, and are not subject to stringent regulatory requirements[5].

In contrast, digital therapeutics are specifically developed to deliver clinical interventions for the prevention, management, or treatment of diseases. They are supported by robust clinical evidence, often derived from randomized controlled trials or real-world studies, and are intended to produce measurable therapeutic outcomes. Many DTx products require regulatory approval as Software as a Medical Device (SaMD) and may even be prescribed by healthcare professionals[6].

Another key distinction lies in integration with pharmacotherapy and clinical practice. DTx are frequently used alongside conventional drug therapy to enhance treatment effectiveness, improve medication adherence, and enable personalized care through continuous monitoring and feedback. Wellness apps, on the other hand, function independently of formal medical treatment and are not typically integrated into clinical decision-making. Thus, the defining features of DTx include clinical intent, evidence-based validation, regulatory oversight, and therapeutic impact, which clearly differentiate them from general digital health and wellness applications[7].

Rationale for Adjunct Use of Digital Therapeutics with Pharmacotherapy

Digital therapeutics (DTx) are integrated with pharmacotherapy to overcome limitations of conventional drug treatment, including poor

medication adherence, lack of continuous monitoring, and limited behavioral support. DTx enhance treatment outcomes through personalized and data-driven interventions such as reminders, educational content, and real-time health monitoring. They also support behavioral modification through cognitive behavioral therapy (CBT), lifestyle coaching, and gamification strategies, particularly in chronic diseases like diabetes, hypertension, and mental health disorders. Additionally, DTx contribute to personalized medicine by analyzing patient-specific data and optimizing treatment recommendations for improved clinical outcomes[8].

Table 1: Rationale for Combining Digital Therapeutics with Pharmacotherapy

Limitation of Pharmacotherapy Alone	Role of Digital Therapeutics (DTx)	Impact on Patient Outcomes
Poor medication adherence	Reminders, alerts, behavioral nudges	Improved compliance and efficacy
Lack of continuous monitoring	Real-time data tracking (e.g., vitals)	Early detection of complications
Limited patient engagement	Interactive interfaces, gamification	Increased patient involvement
Absence of behavioral support	CBT, lifestyle modification programs	Better disease management
Variability in patient response	Data-driven personalization	Optimized therapy outcomes
Infrequent clinical follow-up	Remote monitoring and feedback	Reduced hospital visits

Table 2: Examples of Disease Areas Benefiting from Adjunct DTx

Disease Area	Role of Pharmacotherapy	Adjunct Role of DTx
Diabetes	Glycemic control (e.g., insulin)	Glucose monitoring, diet & activity tracking
Depression	Antidepressants	Cognitive behavioral therapy, mood tracking
Hypertension	Antihypertensive drugs	BP monitoring, lifestyle modification
Asthma/COPD	Bronchodilators, corticosteroids	Inhaler usage tracking, symptom monitoring
Substance use disorder	Pharmacological support	Behavioral therapy, relapse prevention tools

2. Concept and Classification of Digital Therapeutics

Digital therapeutics (DTx) are structured, software-based interventions designed to deliver clinically validated therapeutic outcomes. Their conceptual foundation lies in combining medical science with digital technology to influence patient behavior, monitor health status, and support disease management. Based on their mode of use and regulatory status, DTx can be broadly classified into distinct categories.

2.1 Types of Digital Therapeutics

Digital therapeutics (DTx) can be classified based on their mode of use and regulatory status. Based on mode of use, standalone DTx function independently without pharmacotherapy and are mainly used for conditions where behavioral or cognitive interventions are sufficient, such as insomnia or mild mental health disorders. Adjunct DTx are used alongside pharmacotherapy to improve treatment outcomes through medication adherence support, patient monitoring, and

behavioral interventions, particularly in chronic diseases like diabetes and cardiovascular disorders[9].

Based on regulatory status, prescription digital therapeutics (PDTx) require authorization from healthcare professionals, undergo strict clinical validation, and are integrated into formal healthcare systems for disease management. In contrast, non-prescription DTx are available directly to consumers, generally have fewer regulatory requirements, and are mainly focused on prevention, early intervention, and self-management[10].

Table 3: Classification of Digital Therapeutics

Classification Basis	Type	Key Features	Examples of Use
Mode of Use	Standalone	Independent therapy	Insomnia management
	Adjunct	Used with pharmacotherapy	Diabetes, depression
Regulatory Status	Prescription (PDTx)	Clinically validated, physician-prescribed	Substance use disorder treatment
	Non-prescription	Direct-to-consumer, preventive focus	Lifestyle and early intervention

2.2 Mechanisms of Action of Digital Therapeutics

Digital therapeutics (DTx) produce therapeutic effects through behavioral, cognitive, and data-driven approaches rather than direct biochemical action. They promote behavioral modification using reminders, habit formation, and reinforcement strategies to improve healthy behaviors and medication adherence. Many DTx also incorporate cognitive behavioral therapy (CBT) techniques to help manage conditions such as anxiety, depression, and addiction by modifying thought patterns and emotional responses. In addition, DTx enable real-time monitoring through mobile applications and wearable devices, allowing continuous tracking of patient parameters and providing immediate personalized feedback. Advanced therapeutic algorithms analyze patient-specific data to tailor interventions according to individual needs. DTx also improve patient education and engagement by delivering structured health information, increasing disease awareness, and encouraging active participation in healthcare management[10].

Table 4: Mechanisms of Action and Their Therapeutic Impact

Mechanism	Description	Therapeutic Impact
Behavioral modification	Habit formation, reminders	Improved adherence and lifestyle changes
Cognitive interventions	CBT-based strategies	Better mental health outcomes
Real-time monitoring	Continuous tracking of patient data	Early detection and intervention
Personalized algorithms	Data-driven customization	Optimized individual therapy
Patient education	Information and guidance delivery	Increased awareness and engagement

3. Integration with Pharmacotherapy

3.1 Role in Improving Therapeutic Outcomes

Digital therapeutics (DTx) improve therapeutic outcomes by supporting patients throughout the treatment process and complementing pharmacotherapy. While medications target the biological cause of disease, DTx help ensure proper medicine use, encourage behavioral modifications, and facilitate timely clinical interventions. This integration contributes to better disease control, reduced complications and hospitalizations, and improved quality of life. In chronic diseases requiring long-term management, DTx help maintain consistent therapeutic effectiveness and minimize variations in treatment response[11].

3.2 Medication Adherence and Patient Monitoring

Medication non-adherence is a significant challenge in pharmacotherapy, and DTx help address this through automated medication reminders, digital adherence tracking, and feedback systems that encourage patient compliance. Additionally, DTx enable continuous patient monitoring through mobile applications and wearable devices that track parameters such as blood glucose, blood pressure, physical activity, and symptom progression in real time. This supports early detection of treatment failure or adverse effects, enables data-driven dose adjustments, and reduces the need for frequent hospital visits[12].

3.3 Application Across Disease Areas

The combined use of DTx and pharmacotherapy has shown benefits across several disease areas. In diabetes, DTx support glucose monitoring, dietary management, and adherence to antidiabetic therapy, improving glycemic control. In cardiovascular diseases, they assist in blood pressure monitoring, lifestyle management, and risk reduction alongside antihypertensive and lipid-lowering drugs. In mental health disorders, DTx incorporating cognitive behavioral therapy enhance the effectiveness of antidepressants and anxiolytics while reducing relapse rates. For respiratory disorders such as asthma and COPD, digital tools monitor inhaler use, symptoms, and environmental triggers to improve treatment outcomes. In substance use disorders, DTx provide behavioral support and relapse prevention strategies together with pharmacological therapy[13].

Table 5: Integration of Digital Therapeutics with Pharmacotherapy Across Disease Areas

Disease Area	Pharmacotherapy Role	DTx Contribution	Outcome Improvement
Diabetes	Glycemic control	Glucose tracking, diet & activity monitoring	Better HbA1c control
Cardiovascular disease	BP and lipid management	BP monitoring, lifestyle coaching	Reduced cardiovascular risk
Depression/Anxiety	Neurochemical regulation	CBT, mood tracking	Improved symptom control
Asthma/COPD	Bronchodilation, inflammation control	Inhaler tracking, symptom alerts	Reduced exacerbations
Substance use disorder	Craving suppression, relapse prevention	Behavioral therapy, digital support programs	Lower relapse rates

4. Clinical Evidence and Outcomes

The clinical value of digital therapeutics (DTx) as adjuncts to pharmacotherapy is increasingly supported by a growing body of randomized controlled trials (RCTs) and real-world evidence (RWE). These studies evaluate not only clinical efficacy but also safety, usability, and long-term impact on disease management.

4.1 Clinical Trials and Real-World Evidence

The clinical validation of digital therapeutics (DTx) is mainly based on randomized controlled trials (RCTs), which are considered the gold standard for evaluating therapeutic effectiveness. Many prescription DTx have demonstrated benefits in improving clinical outcomes such as glycemic control, symptom reduction, and relapse prevention. In addition to RCTs, real-world evidence (RWE) collected from observational studies, patient registries, and digital health data helps evaluate the long-term performance of DTx in routine clinical practice. RWE is useful for assessing long-term effectiveness, patient adherence, engagement, and outcomes across diverse populations. Together, RCTs and RWE strengthen the evidence base for regulatory approval and clinical decision-making[14].

4.2 Efficacy and Safety

Digital therapeutics have shown significant clinical benefits when combined with pharmacotherapy. They contribute to improved disease-specific outcomes such as reduced HbA1c levels in diabetes, lower depression and anxiety scores, better medication adherence, and reduced hospitalizations and disease-related complications. In terms of safety, DTx are generally considered low-risk because they do not produce direct pharmacological effects. However, concerns remain regarding data privacy, cybersecurity risks, inaccurate recommendations, digital fatigue, and improper use. Therefore, regulatory-approved DTx must demonstrate both clinical efficacy and safety before receiving authorization for use[15].

4.3 Limitations of Current Evidence

Despite promising results, several limitations affect the current evidence supporting DTx. Many studies are short-term, limiting knowledge about sustained long-term benefits. Some clinical trials include small patient populations, reducing generalizability. Variations in study design, endpoints, and patient populations also create inconsistencies in results. Furthermore, treatment outcomes are highly dependent on patient engagement and adherence to digital interventions. Publication bias, where positive findings are reported more frequently, and the lack of standardized guidelines for evaluating DTx efficacy remain additional challenges in this field[16].

Table 6: Summary of Clinical Evidence for Digital Therapeutics

Parameter	Findings	Implications
Clinical trials (RCTs)	Demonstrate efficacy in multiple disease areas	Support regulatory approval
Real-world evidence	Reflects performance in routine practice	Validates long-term applicability
Efficacy outcomes	Improved biomarkers and symptom control	Enhanced therapeutic effectiveness
Safety profile	Generally low risk, non-invasive	Favorable for widespread use

Evidence limitations	Short duration, small samples, variability	Need for more robust and standardized studies

5. Regulatory Landscape

The regulatory framework for digital therapeutics (DTx) is evolving to ensure safety, efficacy, and quality while accommodating the unique characteristics of software-based interventions. Most DTx are regulated under the concept of Software as a Medical Device (SaMD), with region-specific approval pathways and increasing emphasis on lifecycle oversight, including post-market monitoring[17].

5.1 Software as a Medical Device (SaMD)

Software as a Medical Device (SaMD) refers to software designed for medical purposes without being part of a physical medical device. Most digital therapeutics (DTx) fall into this category as they are used for disease prevention, diagnosis, management, or treatment. SaMD-based DTx function as standalone therapeutic software and require clinical validation, risk-based classification, and continuous lifecycle management, including development, deployment, and software updates. Regulatory authorities evaluate these products based on intended use, risk level, and supporting clinical evidence before approval[18].

5.2 Approval Pathways (US, EU, Global)

Regulatory approval pathways for DTx differ across countries but generally follow evidence-based and risk-oriented frameworks. In the United States, the Food and Drug Administration (FDA) regulates DTx through pathways such as 510(k), De Novo classification, and Premarket Approval (PMA), along with initiatives like the Digital Health Software Precertification Program. In the European Union, DTx require CE marking under the Medical Device Regulation (MDR) to confirm compliance with safety and performance standards. Globally, countries such as Japan and Canada are adopting regulations aligned with international standards established by the International Medical Device Regulators Forum (IMDRF)[19].

5.3 Post-Market Surveillance

Post-market surveillance (PMS) is an essential aspect of DTx regulation because software products are frequently updated and modified. Continuous monitoring helps ensure patient safety, therapeutic effectiveness, and data integrity after market approval. PMS activities include tracking safety and performance metrics, collecting real-world evidence and patient feedback, reporting adverse events or software malfunctions, and reassessing clinical effectiveness after software updates. Regulatory agencies such as the FDA require developers to maintain software change controls and submit risk assessments for updates to ensure that modifications do not compromise safety or efficacy[20].

Table 7: Comparison of Regulatory Frameworks for Digital Therapeutics

Region	Regulatory Authority	Approval Pathway	Key Features
United States	FDA	510(k), De Novo, PMA	Risk-based classification, innovation support
European Union	MDR (CE marking)	Conformity assessment	Strict safety and performance requirements

Global (Others)	National agencies + IMDRF	Region-specific pathways	Increasing harmonization efforts

6. Technological Framework

The effectiveness of digital therapeutics (DTx) as adjuncts to pharmacotherapy relies heavily on a robust technological infrastructure that supports the seamless capture, processing, and secure delivery of therapeutic interventions. This framework includes cloud-based platforms, mobile apps, sensors or wearables, and backend analytics systems that work together to collect real-world physiological and behavioral data, transform it into actionable insights, and deliver personalized, adaptive interventions in real time. Such a system enables continuous monitoring and feedback loops between patients and clinicians, allowing interventions to be tailored to individual needs while maintaining scalability across diverse patient populations. By integrating data from electronic health records, remote monitoring devices, and user-reported outcomes, the technological backbone of DTx ensures that pharmacological treatment is complemented by consistent, evidence-informed, and digitally mediated support, thereby enhancing adherence, safety, and long-term clinical outcomes[21].

6.1 Platforms: Mobile Applications, Wearables, and AI Integration

Digital therapeutics (DTx) are mainly delivered through mobile applications, web-based platforms, wearable devices, and AI-integrated systems. Mobile applications provide therapeutic interventions such as medication reminders, educational content, and behavioral therapy programs, improving patient engagement and treatment adherence. Wearable devices like smartwatches and biosensors continuously monitor physiological parameters such as heart rate, activity levels, and sleep patterns, supporting real-time health assessment. Artificial intelligence (AI) and machine learning further enhance DTx by analyzing patient data, predicting disease progression, and enabling personalized and adaptive treatment strategies based on individual responses[22].

6.2 Data Collection and Interoperability

A major advantage of DTx is their ability to continuously collect and process patient data from sources such as symptom logs, wearable sensors, and electronic health records (EHRs). These platforms gather information related to clinical parameters, medication adherence, lifestyle factors, and patient-reported outcomes, allowing healthcare providers to monitor patient progress and make timely treatment adjustments. Effective interoperability with EHRs and healthcare systems is essential for seamless data exchange. Standardized protocols such as APIs and HL7/FHIR support secure and structured communication, improving coordinated care and clinical decision-making[23].

6.3 Cybersecurity Considerations

Cybersecurity is a critical component of DTx because of the sensitive nature of patient health data. Ensuring data privacy, integrity, and system security is necessary to maintain patient trust and comply with regulations. Important cybersecurity measures include data encryption, access control through authentication and authorization systems, compliance with data protection laws such as GDPR and HIPAA, risk management to identify cyber threats, and secure software updates that prevent the introduction of vulnerabilities[24].

Table 8: Components of Technological Framework in Digital Therapeutics

Component	Description	Role in DTx
Mobile applications	Software interface for users	Delivery of therapeutic interventions
Wearable devices	Sensors and tracking tools	Real-time physiological monitoring
AI/ML algorithms	Data analysis and predictive modeling	Personalized treatment and decision support
Data systems	Storage and processing infrastructure	Continuous data collection and analysis
Interoperability	Integration with healthcare systems	Coordinated and efficient care delivery
Cybersecurity	Data protection and system security measures	Ensures privacy, safety, and regulatory compliance

7. Commercial and Market Perspectives

7.1 Business Models

Digital therapeutics (DTx) use various business models to support adoption and revenue generation. Direct-to-consumer (DTC) models provide DTx directly to patients through apps or subscription platforms, mainly for self-management and prevention. Business-to-business (B2B) models involve partnerships with hospitals, healthcare providers, or employers to integrate DTx into healthcare programs. In the business-to-business-to-consumer (B2B2C) approach, insurers or pharmaceutical companies deliver DTx as part of treatment packages. Some DTx also follow a prescription-based model, where clinicians prescribe them similarly to drugs or medical devices[25].

7.2 Reimbursement and Pricing

Reimbursement is a major factor influencing the adoption of DTx. Coverage may come from private or public insurance providers, employer-sponsored healthcare programs, or government digital health initiatives. Pricing models commonly include subscription-based payments, one-time licensing fees, and outcome-based or value-based pricing. However, challenges such as the absence of standardized reimbursement frameworks, limited awareness among payers, and difficulties in proving long-term cost-effectiveness continue to affect wider adoption[26].

7.3 Industry Adoption and Partnerships

The expansion of the DTx market is supported by collaborations among pharmaceutical companies, technology firms, healthcare providers, and insurers. Pharma–DTx partnerships help combine digital tools with medications to improve treatment outcomes. Technology collaborations enhance DTx capabilities through AI, cloud computing, and advanced analytics. Hospitals and clinics increasingly use DTx for remote monitoring and chronic disease management, while insurers work with DTx companies to establish reimbursement models and demonstrate economic value. These partnerships improve scalability, market access, and integration of DTx into routine healthcare practice[27].

Table 9: Commercial Aspects of Digital Therapeutics

Aspect	Key Features	Implications
Business models	DTC, B2B, B2B2C, prescription-based	Determines reach and scalability
Reimbursement	Insurance, employer, government support	Influences adoption and accessibility
Pricing strategies	Subscription, licensing, value-based	Affects affordability and sustainability
Industry partnerships	Pharma, tech, healthcare collaborations	Drives innovation and integration
Market challenges	Regulatory gaps, reimbursement barriers	Slows widespread adoption

8.1 Patient Engagement and Usability

Patient engagement plays a vital role in the effectiveness of digital therapeutics (DTx), as treatment success depends on consistent usage. User-friendly interfaces, simple navigation, and clear instructions improve usability across different patient groups. Personalization through tailored reminders, feedback, and content enhances adherence and patient satisfaction. Behavioral strategies such as gamification, goal setting, and motivational feedback further support long-term engagement. In addition, involvement of healthcare professionals in monitoring and feedback strengthens patient commitment. Poor usability or overly complex systems can reduce adherence and limit therapeutic benefits[28].

8.2 Data Privacy and Ethical Considerations

DTx collect and process sensitive health information, making data privacy and ethical practices essential. Patient data must be protected through encryption, secure storage, and controlled access systems. Patients should be fully informed about how their data is collected, used, and shared through proper informed consent procedures. Transparency regarding data ownership and accessibility is necessary to maintain trust. Ethical concerns may also arise from non-transparent algorithms or biased decision-making systems. Compliance with regulations such as GDPR and HIPAA is important to ensure responsible and ethical use of DTx. Failure to address these concerns can reduce patient trust and hinder adoption[29].

8.3 Accessibility and Digital Divide

Accessibility remains a significant challenge in the widespread adoption of DTx. Limited digital literacy may prevent some patients from effectively using digital health technologies. Economic barriers, including the cost of devices, internet access, and subscription services, can further restrict access. Geographic disparities, particularly in rural or underserved regions, may also limit the availability of digital infrastructure. Therefore, DTx should be designed to support different languages, age groups, and individuals with disabilities to ensure inclusivity and equitable healthcare access. Addressing the digital divide is essential for reducing healthcare disparities and ensuring that the benefits of DTx are available to all populations[30].

Table 10: Patient-Centric and Ethical Considerations in Digital Therapeutics

Aspect	Key Considerations	Impact on DTx Implementation
Patient engagement	Usability, personalization, motivation	Improved adherence and outcomes
Data privacy	Encryption, secure access, compliance	Builds trust and ensures legal safety
Ethical concerns	Consent, data ownership, algorithm transparency	Promotes responsible use

Accessibility	Digital literacy, affordability, infrastructure	Determines reach and inclusivity
Digital divide	Socioeconomic and geographic disparities	Affects equitable healthcare delivery

9. Challenges, Future Perspectives, and Conclusion

The integration of digital therapeutics (DTx) with pharmacotherapy presents significant opportunities, yet several clinical, regulatory, technological, and societal challenges must be addressed to enable widespread adoption and sustained impact.

9.1 Key Barriers

Although digital therapeutics (DTx) show promising potential in combination with pharmacotherapy, several barriers limit their widespread adoption. Limited large-scale and long-term clinical studies reduce confidence among healthcare professionals and regulators. Variability in regulatory approval pathways across countries creates challenges for developers and delays market access. Reimbursement limitations and the absence of standardized payment models further affect accessibility and commercial success. In addition, physician resistance, difficulties in integrating DTx into clinical workflows, declining patient engagement due to digital fatigue, and concerns related to data privacy and cybersecurity remain important obstacles[31].

9.2 FUTURE TRENDS

The future of DTx is expected to be driven by advancements in technology and evolving healthcare systems. Integration of artificial intelligence (AI) will improve personalization, predictive analytics, and adaptive treatment strategies. DTx applications are also expanding into areas such as oncology, neurological disorders, and rare diseases. Increased use of real-world evidence will strengthen regulatory approvals and clinical acceptance. Furthermore, value-based healthcare models are likely to link reimbursement with clinical outcomes and cost-effectiveness. Greater global regulatory harmonization and stronger collaborations between pharmaceutical and technology companies are expected to support the development of integrated drug–DTx therapies and broader adoption in healthcare practice[32].

10. CONCLUSION

Digital therapeutics are emerging as a valuable complement to conventional pharmacotherapy, offering opportunities to enhance treatment adherence, enable continuous monitoring, and support personalized care. Their ability to address behavioral and lifestyle factors provides an added dimension that traditional drug therapy alone cannot fully achieve.

For successful integration into routine clinical practice, it is essential to strengthen clinical evidence, establish clear regulatory and reimbursement frameworks, and ensure patient-centric design with robust data protection measures. Continued collaboration among healthcare providers, regulators, technology developers, and pharmaceutical companies will be crucial in unlocking the full potential of DTx in modern healthcare systems.

REFERENCES

1. Wang C, Lee C, Shin H. Digital therapeutics from bench to bedside. NPJ Digital Medicine. 2023;6(1):38. doi:10.1038/s41746-023-00777-z.
2. Phan P, Mitragotri S, Zhao Z. Digital therapeutics in the clinic. Bioengineering &

Translational Medicine. 2023;8(4):e10536. doi:10.1002/btm2.10536.
3. Mimoso I, Figueiredo T, Midão L, et al. Co-creation in the development of digital therapeutics: a narrative review. International Journal of Environmental Research and Public Health. 2024;21(12):1589. doi:10.3390/ijerph21121589.
4. Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. Journal of Family Medicine and Primary Care. 2020;9(5):2207-2213. doi:10.4103/jfmpc.jfmpc_105_20.
5. Khan PA, Badole PJ, Shaikh D. Telemedicine and digital health: the future for pharmaceutical companies and health care. Indian Journal of Pharmacology. 2026;58(1):24-34. doi:10.4103/ijp.ijp_452_24.
6. Huh KY, Oh J, Lee S, Yu KS. Clinical evaluation of digital therapeutics: present and future. Healthcare Informatics Research. 2022;28(3):188-197. doi:10.4258/hir.2022.28.3.188.
7. Rajendran A, Kella A, Narayanasamy D. The revolution of digital therapeutics (DTx) in the pharmaceutical industry and their quality impacts. Cureus. 2024;16(8):e66792. doi:10.7759/cureus.66792.
8. Li S, Tao J, Tang J, Chu Y, Wu H. Digital therapeutics as an emerging new therapy for diabetes mellitus: potentials and concerns. Endocrine Connections. 2024;13(9):e240219. doi:10.1530/EC-24-0219.
9. Fürstenau D, Gersch M, Schreiter S. Digital therapeutics (DTx). Business & Information Systems Engineering. 2023;65:349-360. doi:10.1007/s12599-023-00804-z.
10. Divatia S, Foster T, Cui S, Tapiavala V, Fortuna KL. Accessibility and equity considerations in the clinical validation of prescription digital therapeutics: a scoping review. mHealth. 2026;12:10. doi:10.21037/mhealth-25-12.
11. Biskupiak Z, Ha VV, Rohaj A, Bulaj G. Digital therapeutics for improving effectiveness of pharmaceutical drugs and biological products: preclinical and clinical studies supporting development of drug + digital combination therapies for chronic diseases. Journal of Clinical Medicine. 2024;13(2):403. doi:10.3390/jcm13020403.
12. Kardas P, Bennett B, Borah B, et al. Medication non-adherence: reflecting on two decades since WHO adherence report and setting goals for the next twenty years. Frontiers in Pharmacology. 2024;15:1444012. doi:10.3389/fphar.2024.1444012.
13. Kardas P, Bennett B, Borah B, et al. Medication non-adherence: reflecting on two decades since WHO adherence report and setting goals for the next twenty years. Frontiers in Pharmacology. 2024;15:1444012. doi:10.3389/fphar.2024.1444012.
14. Koller C, Blanchard M, Hügle T. Assessment of digital therapeutics in decentralized clinical trials: a scoping review. PLOS Digital Health. 2025;4(6):e0000905. doi:10.1371/journal.pdig.0000905.
15. Shimu SJ, Akter S, Rahman MM, et al. Integrating mental health into diabetes care: closing the treatment gap for better outcomes—a systematic review. Medical Sciences. 2025;13(4):259. doi:10.3390/medsci13040259.
16. Kim HS. Apprehensions about excessive belief in digital therapeutics: points of concern excluding merits. Journal of Korean Medical Science. 2020;35(45):e373. doi:10.3346/jkms.2020.35.e373.
17. Kim HS. Apprehensions about excessive belief in digital therapeutics: points of concern excluding merits. Journal of Korean Medical

Science. 2020;35(45):e373. doi:10.3346/jkms.2020.35.e373.
18. Hong JS, Wasden C, Han DH. Introduction of digital therapeutics. Computer Methods and Programs in Biomedicine. 2021;209:106319. doi:10.1016/j.cmpb.2021.106319.
19. Armeni P, Polat I, De Rossi LM, Diaferia L, Meregalli S, Gatti A. Exploring the potential of digital therapeutics: an assessment of progress and promise. Digital Health. 2024;10:20552076241277441. doi:10.1177/20552076241277441.
20. Raj N, Fernandes S, Charyulu NR, Dubey A, GS R, Hebbar S. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Therapeutic Advances in Drug Safety. 2019;10:2042098619865413. doi:10.1177/2042098619865413.
21. Rajendran A, Kella A, Narayanasamy D. The revolution of digital therapeutics (DTx) in the pharmaceutical industry and their quality impacts. Cureus. 2024;16(8):e66792. doi:10.7759/cureus.66792.
22. Jiang N, Yu X, Yang Y, et al. Digital therapeutics in China: comprehensive review. Journal of Medical Internet Research. 2025;27. doi:10.2196/70955.
23. Hu S, Song D, Wan S, et al. Digital health: current applications, challenges, and future directions for enhancing healthcare quality and safety. Frontiers in Public Health. 2025;13:1646802. doi:10.3389/fpubh.2025.1646802.
24. Aldosari B. Cybersecurity in healthcare: new threat to patient safety. Cureus. 2025;17(5):e83614. doi:10.7759/cureus.83614.
25. Carrera A, Manetti S, Lettieri E. Rewiring care delivery through digital therapeutics (DTx): a machine learning-enhanced assessment and development (M-LEAD) framework. BMC Health Services Research. 2024;24(1):237. doi:10.1186/s12913-024-10702-z.
26. Carrera A, Manetti S, Lettieri E. Rewiring care delivery through digital therapeutics (DTx): a machine learning-enhanced assessment and development (M-LEAD) framework. BMC Health Services Research. 2024;24(1):237. doi:10.1186/s12913-024-10702-z.
27. Rajendran A, Kella A, Narayanasamy D. The revolution of digital therapeutics (DTx) in the pharmaceutical industry and their quality impacts. Cureus. 2024;16(8):e66792. doi:10.7759/cureus.66792.
28. Lee H, Choi EH, Shin JU, et al. The impact of intervention design on user engagement in digital therapeutics research: factorial experiment with a mixed methods study. JMIR Formative Research. 2024;8:e51225. doi:10.2196/51225.
29. Conduah AK, Ofoe S, Siaw-Marfo D. Data privacy in healthcare: global challenges and solutions. Digital Health. 2025;11:20552076251343959. doi:10.1177/20552076251343959.
30. Borges do Nascimento IJ, Abdulazeem H, Vasanthan LT, et al. Barriers and facilitators to utilizing digital health technologies by healthcare professionals. NPJ Digital Medicine. 2023;6(1):161. doi:10.1038/s41746-023-00899-4.
31. Bang M, Park JH. Strategies to increase patients' adherence to digital therapeutics for musculoskeletal diseases: a narrative review. Yonsei Medical Journal. 2026;67(3):175.
32. Huh KY, Oh J, Lee S, Yu KS. Clinical evaluation of digital therapeutics: present and future. Healthcare Informatics Research. 2022;28(3):188-197. doi:10.4258/hir.2022.28.3.188.

HOW TO CITE: Chaya Rani, Amit Kumar, Akshay Sharma, Gurvinder Pal Singh, Digital Therapeutics as Adjuncts to Pharmacotherapy: Regulatory Landscape, Clinical Evidence, and Commercial Challenges, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 8053-8067. https://doi.org/ 10.5281/zenodo.20459401